TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02258893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NO2 Scrubber
Description: an NO2 scrubber that removes NO2 and particles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NO2 Scrubber
Description: an NO2 scrubber that removes NO2 and particles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NO2 Scrubber
Description: an NO2 scrubber that removes NO2 and particles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NO2 Scrubber
Description: an NO2 scrubber that removes NO2 and particles
Study: NCT03785964

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Sugar pill manufactured to mimic nirogacestat 50 mg tablet
Study: NCT03688516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manipulation of valence and modality
Description: mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Manipulation of valence and modality
Description: mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
Study: NCT00807053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide HFA
Description: 75 mcg Ciclesonide HFA versus Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide HFA
Description: 150 mcg Ciclesonide HFA versus Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide HFA
Description: 300 mcg Ciclesonide HFA versus Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03688516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spatial and recognition memory
Description: mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Spatial and recognition memory
Description: mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Source and content memory
Description: mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Source and content memory
Description: mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
Study: NCT03124836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Oximeter Sensor
Study: NCT03374540

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 15/20 mg

Intervention type: DRUG
Intervention: Vitamin K antagonist (VKA)
Description: Individually adjusted dose
Study: NCT01991522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Curriculum Group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed learning group
Study: NCT01162902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem treated group
Description: Diltiazem 180mg for 9 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol treated group
Description: Bisoprolol 5mg for 9 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan treated group
Description: Candesartan 32mg for 9 months
Study: NCT02155335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prefilled Syringe delivery of Golimumab
Description: Golimumab 50 mg solution for subcutaneous injection using prefilled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smartject Device delivery of Golimumab
Description: Golimumab 50 mg solution for subcutaneous injection using Smartject Device.
Study: NCT03050879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Tracer
Description: Laparoscopic gastrectomy with lymph node dissection for gastric cancer using Indocyanine Green Tracer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green Tracer
Description: Laparoscopic gastrectomy with lymph node dissection for gastric cancer using Indocyanine Green Tracer
Study: NCT04377607

Intervention type: OTHER
Intervention: File scanning
Description: RBC, HGB, HCT, MCH, MCV, MCHC, WBC values will be noted in the hemogram test performed at the time of initial admission

Intervention type: OTHER
Intervention: File scanning
Description: RBC, HGB, HCT, MCH, MCV, MCHC, WBC values will be noted in the hemogram test performed at the time of initial admission

Intervention type: OTHER
Intervention: File scanning
Description: RBC, HGB, HCT, MCH, MCV, MCHC, WBC values will be noted in the hemogram test performed at the time of initial admission
Study: NCT00302003

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or subcutaneously
Study: NCT00283439

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 531
Description: Planned Cohorts:~1. 100 mcg,~2. 300 mcg,~3. 700 mcg,~4. 1000 mcg;~   Optional Cohorts:~5. cohort expansion,~6. schedule change,~7. new dose
Study: NCT02047799

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Calcitriol (1000 UI)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Placebo
Study: NCT02258893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NO2 Scrubber
Description: an NO2 scrubber that removes NO2 and particles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEPA filter
Description: a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEPA filter
Description: a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEPA filter
Description: a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEPA filter
Description: a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEPA filter
Description: a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEPA filter
Description: a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: a control filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: a control filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: a control filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: a control filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: a control filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: a control filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles
Study: NCT02950831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerometry
Description: Record of activity levels using a wrist worn accelerometer
Study: NCT04591782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PomJuice
Description: Drink 8 oz pomegranate juice

Intervention type: OTHER
Group type: OTHER
Intervention: Water
Description: Drink 8 oz water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Water
Description: Drink 8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved in
Study: NCT00993382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celivarone
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celivarone
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celivarone
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo
Description: Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake
Study: NCT03539666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: dietary patterns

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: dietary patterns
Study: NCT03783026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Tablets for oral administration
Study: NCT02445768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive multisensory rehabilitation
Study: NCT01012765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)
Study: NCT03640338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold-Therapy System
Description: After surgery, participants assigned to this group will receive the cold-therapy system to use at the hospital and during the first 2 weeks following discharge.
Study: NCT01012765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium 18µg o.d. delivered via a proprietary inhalation device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium 18µg o.d. delivered via a proprietary inhalation device.
Study: NCT00943332

Intervention type: PROCEDURE
Intervention: femur fracture repair
Description: all participants will have undergone surgical intervention to repair a femur fracture, the investigators will simply be collecting data after the procedure; participants will not be consented until after the procedure
Study: NCT01012765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium 18µg o.d. delivered via a proprietary inhalation device.
Study: NCT03022370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepping Stones and Creating Futures
Description: Stepping Stones consists of 10 sessions. It seeks to strengthen relationships and to transform views on gender and in the process impact on exposure to, or participation in, gender-based violence and HIV risk. These cover gender and peer influences our actions; sex and love; conception and contraception; STIs and HIV; safer sex and condoms; GBV; motivations for behaviour (including influences of alcohol and poverty); and communication skills.~Creating Futures is a facilitated group intervention of eleven sessions. It seeks to strengthen livelihoods. The key sessions include: setting medium term livelihood goals, the need for assets and coping with crises; social resources for livelihoods (trust and community participation); getting and keeping jobs; and savings and spending.
Study: NCT00943332

Intervention type: PROCEDURE
Intervention: femur fracture repair
Description: all participants will have undergone surgical intervention to repair a femur fracture, the investigators will simply be collecting data after the procedure; participants will not be consented until after the procedure

Intervention type: PROCEDURE
Intervention: femur fracture repair
Description: all participants will have undergone surgical intervention to repair a femur fracture, the investigators will simply be collecting data after the procedure; participants will not be consented until after the procedure
Study: NCT05976100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally
Description: Volunteers take 1 capsule (200 mg) of NIOCH-14 as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 once orally. (Total 600 mg NIOCH-14 per day)
Description: Volunteers take 3 capsules (200 mg each) of NIOCH-14 as a single oral dose. (Total 600 mg NIOCH-14 per day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIOCH-14, 200 mg capsule: 6 capsules (200 mg each) of NIOCH-14 per day orally. (Total 1200 mg NIOCH-14 per day)
Description: Single 1200-mg oral dose. (1200-mg dose of the drug is administered by 600 mg twice a day at 8-00 and 20-00 in the hospital and presence of a clinical investigator or a nurse).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days
Description: Volunteers take 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days. (Total 600 mg NIOCH-14 per day for 6 days)
Description: Volunteers take 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days. (Total 1200 mg NIOCH-14 per day for 6 days)
Description: Volunteers take 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days.
Study: NCT01488773

Intervention type: DRUG
Intervention: first prescription of montelukast
Description: The index event (intervention) was defined as the first prescription for montekuast (leukotriene receptor antagonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.

Intervention type: DRUG
Intervention: first prescription of salmeterol
Description: The index event (intervention) was defined as the first prescription for salmeterol (long-acting β2-agonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
Study: NCT01897428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test-Bepotastine salicylate 9.64 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference-bepotastine besilate 10 mg
Study: NCT00495807

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: No Words
Description: Without any words was given during pain management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive words
Description: Positive words was given to PCA pain management patients at different time point,i.e. 3h, 6h, 12h and 18h.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Partially Negative Words
Description: Partially negative words was given during PCA pain management at different time point,i.e. 3h, 6h, 12h and 18h.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Totally Negative Words
Description: Totally negative words was given during PCA pain management at different time points, i.e. 3h, 6h, 12h and 18h
Study: NCT02814344

Intervention type: DEVICE
Intervention: Electrohysterography

Intervention type: DEVICE
Intervention: Electrohysterography
Study: NCT01973998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: PDE4 inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive substance.
Study: NCT00756990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depot Naltrexone
Description: 228mg of injectable naltrexone
Study: NCT02672462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radio frequency renal denervation system (Golden Leaf GL-06E15A)
Study: NCT01012765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium 18µg o.d. delivered via a proprietary inhalation device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium 18µg o.d. delivered via a proprietary inhalation device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium 18µg o.d. delivered via a proprietary inhalation device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to indacaterol o.d. delivered via SDDPI
Study: NCT02848807

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NUTRIDRINK Compact Protein
Description: high-energy, high-protein, oral liquid nutritional supplement; dosage: 2x125 ml per day, 7 days per week for 12 weeks (3 months)
Study: NCT01113723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic bronchoscope
Description: Fiberoptic bronchoscope device

Intervention type: DEVICE
Group type: OTHER
Intervention: CMAC
Description: CMAC Device
Study: NCT01378442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fitness training program
Description: Experimental: high level training group. The experimental group received training for 40 min per day 3 times a week for 12 weeks. The hVCT program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, cycling for 20 min, and a cool-down exercise for 5 min.~Experimental: low level training group. The experimental group received training for 40 min per day 1-2 times a week for 12 weeks. The program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, fitness training for 20 min, and a cool-down exercise for 5 min.~Control:The control group will not receive fitness training program but maintain the usual life style.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fitness training program
Description: Experimental: high level training group. The experimental group received training for 40 min per day 3 times a week for 12 weeks. The hVCT program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, cycling for 20 min, and a cool-down exercise for 5 min.~Experimental: low level training group. The experimental group received training for 40 min per day 1-2 times a week for 12 weeks. The program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, fitness training for 20 min, and a cool-down exercise for 5 min.~Control:The control group will not receive fitness training program but maintain the usual life style.
Study: NCT02186665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcitriol ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Study: NCT02712528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil-based

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sevoflurane-sufentanil balanced